SIWA Therapeutics is a privately held preclinical stage biotechnology company that has a monoclonal antibody that targets and destroys senescent cells. Our current therapeutic focus is on certain rare and fast track diseases, including cancer metastasis and muscle wasting diseases, such as muscular dystrophy. Beyond these indications, senescent cells are causally implicated in a wide variety of diseases including: neurodegenerative diseases; autoimmune conditions, and infectious diseases. SIWA is currently optimizing its lead antibody, SIWA 318, and in parallel, seeking partnerships to advance SIWA 318 and other related technologies to broaden and accelerate its development pipeline.
Company Details
- Employees
- 9
- Address
- 400 E Randolph St,
- Phone
- +1 (312) 445-8529
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- siwatherapeutics.com
- HQ
- Chicago, Illinois
Siwa Therapeutics Questions
Siwa Therapeutics's helpline number is +1 (312) 445-8529
Siwa Therapeutics's website is siwatherapeutics.com
Siwa Therapeutics's LinkedIn profile is https://www.linkedin.com/company/siwa-therapeutics
Siwa Therapeutics has
9 employees.
View email and phone details for 9
employees at Siwa Therapeutics.
Siwa Therapeutics's industry is
Biotechnology Research
Siwa Therapeutics's top competitors are
Circ Biosciences,
Vanqua Bio,
Xeris Pharmaceuticals, Inc.,
Maia Biotechnology, Inc.,
Tract Therapeutics, Inc.,
Evozyne,
Grove Biopharma, Inc.,
Flashpoint Therapeutics,
Emalex Biosciences,
Exicure.
Siwa Therapeutics's support email address is info@siwatherapeutics.com
Siwa Therapeutics's categories are Biotechnology Research
